NCT01103960 - An Eight-week Randomized,Double-blind Study to Evaluate the Efficacy and Safety of Fixed-dose Combinations of T80+A5 Versus A5 Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With A5 Monotherapy | Biotech Hunter

Enrollment

324

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

August 31, 2011

Conditions

Hypertension

Interventions

DRUG

Telmisartan80mg+Amlodipine5mg

combination therapy

DRUG

amlodipine 5mg

monotherapy

DRUG

Telmisartan80mg+Amlodipine 5mg

combination therapy

Trial Locations (16)

1235.29.86001 Boehringer Ingelheim Investigational Site, Beijing

1235.29.86004 Boehringer Ingelheim Investigational Site, Beijing

1235.29.86006 Boehringer Ingelheim Investigational Site, Changchun

1235.29.86013 Boehringer Ingelheim Investigational Site, Changsha

1235.29.86014 Boehringer Ingelheim Investigational Site, Guangzhou

1235.29.86012 Boehringer Ingelheim Investigational Site, Hangzhou

1235.29.86002 Boehringer Ingelheim Investigational Site, Shanghai

1235.29.86009 Boehringer Ingelheim Investigational Site, Shanghai

1235.29.86010 Boehringer Ingelheim Investigational Site, Shanghai

1235.29.86011 Boehringer Ingelheim Investigational Site, Shanghai

1235.29.86007 Boehringer Ingelheim Investigational Site, Shenyang

1235.29.86008 Boehringer Ingelheim Investigational Site, Tianjin

1235.29.60017 Boehringer Ingelheim Investigational Site, Johor Bahru

1235.29.60016 Boehringer Ingelheim Investigational Site, Kuala Lumpur

1235.29.63018 Boehringer Ingelheim Investigational Site, Metro Manila

1235.29.63019 Boehringer Ingelheim Investigational Site, Quezon City